To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Famotidine (INN) (pronounced /fəˈmɒtɪdiːn/) is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid.
Additional recommended knowledge
Main article: H2-receptor antagonist
Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States, preparations of 10 mg and 20 mg tablets, sometimes in combination with a more traditional antacid, are available OTC. Larger doses still require a prescription.
Famotidine is given to surgery patients before operations to prevent post-operation nausea and to reduce the risk of aspiration pneumonitis.
History and development
It was first marketed in 1985. Pepcid RPD orally-disintegrating tablets (that are not swallowed) was released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.). In the United States, a product called Pepcid Complete is available that combines famotidine with an antacid in a chewable tablet to ameliorate the relatively slow onset of effects. In the UK, this product is known as Pepcidtwo.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Famotidine". A list of authors is available in Wikipedia.|